Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

960 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-28

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy, and thus are widely accepted in clinical practice. Meanwhile, after percutaneous coronary intervention (PCI) using the drug-eluting stents due to coronary artery disease, the administration of one or more antiplatelets is essential to prevent the recurrence of stent thrombosis and myocardial infarction. Combined administration of anticoagulants and antiplatelets significantly lowers the incidence of ischemic events such as stroke and myocardial infarction, however, it also significantly increases the likelihood of bleeding leading to hospitalization, and or even death, thereby significantly affecting the clinical course of the AF patients who underwent PCI. Nevertheless, due to the very high mortality rate of stent thrombosis, the current standard of care guidelines recommend triple therapy with anticoagulants and double antiplatelet therapy (DAPT) in patients with atrial fibrillation for 1 month after coronary intervention, followed by co-administration of NOAC with single antiplatelet agent for 1 year. However, little is known after the optimal therapeutic strategy after 1 year. The purpose of this study is to compare the clinical results of single anticoagulant and clopidogrel combination therapy for maintenance therapy after 1 year in patients with atrial fibrillation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation

NCT01557075

Drug-eluting Stent (DES)

UNKNOWN PHASE4

TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI

NCT03465644

Coronary Stenoses

COMPLETED PHASE4

The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients

NCT03785509

Platelet Aggregation Inhibitors Hydroxymethylglutaryl-coa Reductase Inhibitors Compliance, Medication +3 more

COMPLETED

24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

NCT06014060

Elevated Lipoprotein(a) Level Coronary Artery Disease Drug-Eluting Stent +1 more

RECRUITING NA

Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease

NCT02579499

Coronary Artery Diseasse

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AF patients who had undergone PCI with DES implantation at least 12 months ago will be enrolled in this study. Decision for the antiplatelet agent discontinuation would be determined by randomization. Apixaban or Rivaroxaban would be prescribed to reduce the risk stroke or systemic embolism evoked by AF, and the administration of Warfarin, a vitamin-K dependent anticoagulant, would also be allowed according to attending physician's decision. The following criteria should be followed for the reduction of dosages according to the patient's renal function and other systemic conditions. Warfarin is administered to patients with creatinine clearance \< 15 ml/min or dialysis. The drugs used in this study correspond to the international treatment guidelines after coronary intervention in patients with atrial fibrillation.NOAC and antiplatelet agents would be prescribed upon an outpatient visit. Clinical outcome would be followed for 2 years after study enrollment and randomization.

Screening

* Baseline Serum AST/ALT level
* Creatinine clearance (mL/min)
* Concurrent administration of CYP3A4 agents: Ketoconazole, Itraconazole, Iopinavir/ritonavir, indinavir/ritonavir, conviaptan

\# Dose Adjustment Criteria for Apixaban

@ Meeting 2 of 3 following criteria
* Serum creatinine level \> 1.5 mg/dL
* Body weight under 60 kg
* age over 80 years old

\# Dose Adjustment Criteria for Rivaroxaban
* eGFR from 15-49 mg/min

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NOAC monotherapy

Group Type EXPERIMENTAL

NOAC monotherapy

Intervention Type DRUG

Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.

Dual antithrombotic therapy

Group Type ACTIVE_COMPARATOR

Dual antithrombotic therapy with NOAC and clopidogrel

Intervention Type DRUG

Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NOAC monotherapy

Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.

Intervention Type DRUG

Dual antithrombotic therapy with NOAC and clopidogrel

Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. over 19 years old
2. Patient who underwent PCI with DES more than 12 months ago
3. Non-valvular atrial fibrillation patients requiring long-term anticoagulation

Exclusion Criteria

1. Over 85 years old
2. Pregnancy or Potential Pregnancy
3. Life expectancy within 1 year
4. Patients who refuse or do not understand the written consent form
5. Requiring anticoagulation due to history of mechanical valve replacement, mitral stenosis or deep vein thrombosis
6. Coagulopathy, continuous bleeding, or Hb level below 10 g/dL
7. Intracerebral hemorrhage within 2 months
8. Patients with gastrointestinal hemorrhage within three months of registration
9. Patients diagnosed with a gastrointestinal tumor that requires continuous treatment
10. Patients treated with 1st generation drug-eluting stents (Cypher, Taxus, or Endeavor Sprint)

Minimum Eligible Age

19 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No